Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company, announced the grant of an inducement award on December 9, 2025. The Compensation Committee of the company's Board of Directors approved granting 8,224 restricted stock units (RSUs) to a newly hired employee as part of its 2021 Employment Inducement Incentive Award Plan. This award aligns with Nasdaq Listing Rule 5635(c)(4), designed to incentivize new talent to join the company.

The RSUs will vest in three equal annual installments, contingent upon the employee's continued service with Precision BioSciences. The strategic move highlights Precision's commitment to enhancing its workforce and maintaining its focus on innovative gene editing therapies using its proprietary ARCUS® platform.

Precision BioSciences is dedicated to advancing gene-editing solutions for diseases that currently lack adequate treatment options. The company's ARCUS® platform stands out due to its unique approach to cutting DNA, characterized by its smaller size and simpler structure, which may lead to more precise and effective therapeutic outcomes. The technology supports various sophisticated gene-editing methods, including gene insertion, elimination of harmful genetic sequences, and excision of defective genes.

The company's research pipeline includes in vivo gene editing candidates aimed at delivering lasting cures for a wide spectrum of genetic and infectious diseases. As Precision BioSciences continues to expand its capabilities and workforce, it reinforces its mission to improve life by addressing unmet medical needs through advanced gene editing technologies.

For more information on Precision BioSciences and its initiatives, interested parties can visit their official website at www.precisionbiosciences.com.

Precision BioSciences Inc. (Nasdaq: DTIL) recently announced a grant of 8,224 restricted stock units (RSUs) as part of its 2021 Employment Inducement Incentive Award Plan. This decision reflects the company's strategic moves to attract key talent, a critical factor as it advances its proprietary ARCUS® gene editing technology to address unmet medical needs.

From an investment standpoint, this inducement award can be viewed as a positive signal regarding the company’s growth prospects. By incentivizing new employees with equity, Precision BioSciences demonstrates confidence in its future performance, suggesting that it expects substantial advancements in its gene editing pipeline. Moreover, the nature of the ARCUS platform, which allows for versatile applications such as gene insertion, elimination, and excision, positions the company favorably in a competitive biotech landscape.

Investors should also consider the broader market context for biotechnology companies, particularly those specializing in gene editing. As the industry continues to grapple with regulatory scrutiny and long development timelines, Precision’s ability to attract and retain talent could play a pivotal role in expediting its clinical trials and bringing innovative therapies to market. The focus on diseases with high unmet needs can enhance partnerships with pharmaceutical companies seeking to enhance their pipelines.

Given current trends in the biotech sector, Precision BioSciences may present an attractive opportunity for growth-oriented investors who can tolerate volatility. However, potential investors should maintain a cautious approach, considering factors such as ongoing clinical trial results, funding requirements for further research, and the overall market environment which can influence stock performance.

In summary, while Precision BioSciences' announcement is a positive indicator for potential investors, careful consideration of both company-specific and industry-wide factors is essential before making investment decisions.